GH Research Maintains Strong Buy Rating with $40 Price Target from H.C. Wainwright
PorAinvest
jueves, 21 de agosto de 2025, 3:48 am ET1 min de lectura
GHRS--
GH Research, which operates in the medical technology sector, has a consensus rating of Strong Buy among analysts, with a price target consensus of $32.86. This consensus rating is based on the average of 8 analysts' ratings over the past 3 months, with 8 analysts rating GHRS as a Strong Buy, and none rating it as Hold or Sell [2].
The company's stock has seen significant volatility over the past year, with a one-year high of $20.50 and a one-year low of $6.00. Despite this volatility, analysts remain optimistic about the company's future prospects. The average price target of $32.86 represents a potential 159.35% upside from the current price of $12.67, indicating strong growth expectations [2].
Analysts cite promising developments in GH Research's therapeutic research and development (TRD) program, as well as regulatory progress, as key drivers for their positive outlook. The company's strategic progress and financial stability have also been noted as positive factors [2].
Investors should closely monitor GH Research's developments and remain informed about the company's progress in its clinical trials and regulatory filings. The consensus rating and price targets provide a valuable insight into the market's expectations for GH Research's future performance.
References:
[1] https://www.marketbeat.com/stocks/NASDAQ/GHRS/forecast/
[2] https://www.tipranks.com/stocks/ghrs/forecast
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on GH Research (GHRS) with a price target of $40.00. Trucchio has an average return of 7.6% and a 42.68% success rate on recommended stocks. GH Research has a consensus rating of Strong Buy and a price target consensus of $32.86. The company has a one-year high of $20.50 and a one-year low of $6.00.
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on GH Research (GHRS) with a price target of $40.00. Trucchio, known for his strong track record with an average return of 7.6% and a 42.68% success rate on recommended stocks, remains bullish on GHRS [1].GH Research, which operates in the medical technology sector, has a consensus rating of Strong Buy among analysts, with a price target consensus of $32.86. This consensus rating is based on the average of 8 analysts' ratings over the past 3 months, with 8 analysts rating GHRS as a Strong Buy, and none rating it as Hold or Sell [2].
The company's stock has seen significant volatility over the past year, with a one-year high of $20.50 and a one-year low of $6.00. Despite this volatility, analysts remain optimistic about the company's future prospects. The average price target of $32.86 represents a potential 159.35% upside from the current price of $12.67, indicating strong growth expectations [2].
Analysts cite promising developments in GH Research's therapeutic research and development (TRD) program, as well as regulatory progress, as key drivers for their positive outlook. The company's strategic progress and financial stability have also been noted as positive factors [2].
Investors should closely monitor GH Research's developments and remain informed about the company's progress in its clinical trials and regulatory filings. The consensus rating and price targets provide a valuable insight into the market's expectations for GH Research's future performance.
References:
[1] https://www.marketbeat.com/stocks/NASDAQ/GHRS/forecast/
[2] https://www.tipranks.com/stocks/ghrs/forecast

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios